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Abstract 
To determine whether patient specific numerical simulations of irreversible electroporation (IRE) of the prostate cor-
relates with the treatment effect seen on follow-up MR imaging. Computer models were created using intra-operative 
US images, post-treatment follow-up MR images and clinical data from six patients receiving IRE. Isoelectric contours 
drawn using simulation results were compared with MR imaging to estimate the energy threshold separating treated 
and untreated tissue. Simulation estimates of injury to the neurovascular bundle and rectum were compared with 
clinical follow-up and patient reported outcomes. At the electric field strength of 700 V/cm, simulation estimated 
electric field distribution was not different from the ablation defect seen on follow-up MR imaging (p = 0.43). Simula-
tion predicted cross sectional area of treatment (mean 532.33 ± 142.32 mm2) corresponded well with the treatment 
zone seen on MR imaging (mean 540.16 ± 237.13 mm2). Simulation results did not suggest injury to the rectum or 
neurovascular bundle, matching clinical follow-up at 3 months. Computer simulation estimated zone of irrevers-
ible electroporation in the prostate at 700 V/cm was comparable to measurements made on follow-up MR imaging. 
Numerical simulation may aid treatment planning for irreversible electroporation of the prostate in patients.
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Background
The detection of prostate cancer has shifted to an earlier 
point in disease development, resulting in the increased 
incidence of early-stage small-volume cancer. Conse-
quentially, there has been an emergence of minimally 
invasive surgical interventions designed to provide 
appropriate local oncologic control with negligible treat-
ment related effects on quality of life (van den Bos et al. 
2014; Valerio et al. 2014). Such focal tissue ablation tech-
niques intend to preserve erectile, urinary and rectal 
function by minimizing damage to anatomical features 
such as neurovascular tissues, the urinary sphincter, 
bladder and rectum that surround the prostate. Thermal 
ablation techniques such as cryoablation (Cytron et  al. 
2009; Bahn et  al. 2012; Onik et  al. 2008), high intensity 
focused ultrasound (HIFU) (El Fegoun et al. 2011; Baco 
et  al. 2014; Crouzet et  al. 2014) and focal laser ablation 
(Lindner et  al. 2010) have been evaluated for treatment 
of patients with localized prostate cancer with good short 
term outcomes (Ahmed et al. 2011, 2012). However, lit-
erature suggests that even focal ablation requires careful 
planning and application to avoid injury to vitally healthy 
tissue in the treatment vicinity (Barret et al. 2013).
Irreversible electroporation (IRE) is a new type of focal 
ablation that uses short high voltage electric pulses to 
create persistent micropores in the plasma membranes 
of cells, leading to cell death. IRE has been evaluated 
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for ablation of the prostate in the preclinical (Onik 
et  al. 2007; Neal et  al. 2013) and clinical setting (Neal 
et  al. 2014; Valerio et  al. 2014). Even though the energy 
used during IRE may produce heating in the immediate 
vicinity of the electrodes (Faroja et al. 2013), it has been 
observed to be safe for the focal ablation of tumors adja-
cent to heat sensitive structures such as the bile duct 
(Silk et al. 2014) and the pancreas (Bower et al. 2011) in 
humans. IRE is performed by placing needle electrodes 
in tissue and applying a voltage between the electrodes 
to generate an in vivo ablative electric field. The in vivo 
electric field distribution is determined by the geometry 
of ablation probe placement, the voltage applied between 
the electrodes and the electrical conductivity of the tis-
sue receiving treatment. The therapeutic efficacy and 
treatment outcomes following IRE ablation is therefore 
contingent on the size, shape and consistency of the 
in vivo distribution of this ablative electric field. The abla-
tive electric field used to induce IRE in tissue has been 
reported to be susceptible to heterogeneities in electri-
cal conductivity in the treatment region (Ben-David et al. 
2013). There is concern that such intrinsic redistribution 
of the ablative electric field may cause unintended safety 
effects and also alter the intended volume and shape of 
the final treatment region. Patient specific computer sim-
ulations can model the ablative electric field distribution 
in the prostate using data obtained from pre and intra-
operative imaging, and the treatment parameters. There-
fore, the purpose of this study was to determine whether 
retrospectively constructed patient specific numerical 
simulations can map the treatment effect seen on fol-
low-up MR imaging after irreversible electroporation of 
patient prostate.
Methods
This retrospective single institution study was approved 
by the institutional review board and performed in com-
pliance with the Helsinki Declaration.
Patients and treatment
Data of six consecutive patients treated with IRE in 2013 
(mean age 66.5  years; range 61–70  years) with biopsy 
proven prostate carcinoma was used in this retrospective 
study. Focal ablation was performed within 3–6 months 
of biopsy and 4–6  weeks following MRI. IRE was per-
formed after insertion of needles spaced 10–15 mm apart 
through a transperineal approach under TRUS guid-
ance. Voltages used for treatment delivery was chosen 
to achieve an effective electric field strength of 1600–
1800 V/cm between any pair of ablation probes used for 
treatment delivery, seventy 90  μs pulses were used to 
perform the treatment. Patient characteristics and abla-
tion data are summarized in Table 1. All treatments were 
performed under general anesthesia with intravenous 
muscle blockade to reduce electric pulse induced muscle 
contraction.
Preoperative MR imaging and intra-operative axial 
TRUS acquisitions were recorded, with measurement 
of the prostate in the axial cross-section. Therapy target 
was guided by location of positive biopsy findings, and 
by imaging in two patients who had tumors visible on 
MR imaging. Treatment was planned to achieve 5  mm 
ablation margin encompassing the region suspicious 
for malignancy. Follow-up MRI was performed within 
21  days (±9  days) after IRE treatment. Post-treatment, 
all patients underwent follow up imaging in a tertiary 
referral center on a 1.5  T system (GE, Milwaukee, IL, 
USA) with an endorectal coil and contrast injection. 
The MR protocol used for image acquisition is reported 
in Table 2. Patient reported outcomes regarding urinary 
and sexual function were obtained using a questionnaire 
at their clinic visit, along with PSA measurements within 
4–6 months after treatment.
Image processing
The intra-operative ultrasound image in the axial plane 
corresponding to the midpoint of the treatment zone 
(mid-point of ablation volume) was manually regis-
tered with the pre-operative MR images. The registered 
image set was then annotated to demarcate the ablation 
probes, the outline of the prostate, rectum, neurovascular 
bundles and the tumor (where observable) using OsiriX 
DICOM Viewer (Fig. 1a, b). This annotated image set was 
used to generate the 3D models for the simulation.
Subsequently, the follow-up MR images were also reg-
istered with the intra-operative US images in a similar 
process. The ablation defect was segmented from the 
follow-up imaging. The area of the prostate was meas-
ured from the intra-operative US images, and the follow-
up MR images using GNU image processing software 
(GIMP). The area of the ablation defect was measured 
from the follow-up MR image and simulation results. In 
addition to visual assessment performed by two radiolo-
gists, the influence of post-treatment edema and result-
ing error in registration were evaluated by comparing the 
ratio of the prostate’s area between intra-operative US 
images and the follow-up MR images. The ablation area 
measurements from the follow-up MR image and the 
simulation results were compared in a similar fashion.
Simulation
A numerical model of the Laplace equation was solved 
to estimate the electric field distribution within the tissue 
due to application of voltage between pairs of needle elec-
trodes used for treatment delivery. Techniques previously 
described by Neal et  al. (2012, 2010) and Daniels and 
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Rubinsky (2012) were used to set up and solve the numeri-
cal models. The modeling and simulation techniques were 
developed and validated partly using data generated from 
IRE treatments performed in the kidney and pancreas of a 
large animal model (Wimmer et al. 2013, 2015).
Finite element computer simulations were used to 
estimate in  vivo distribution and magnitude of the abla-
tive electric field within the prostate and surrounding 
anatomic structures. The annotated intra-operative US 
images were imported into Inventor (Autodesk, San Rafael 
CA), and the data was manually segmented. The seg-
mented regions were then used to generate 2.5 mm thick 
3D geometry for each region identified in the US image. 
This specific slice thickness was chosen to roughly corre-
spond to slice thickness (3.5 mm) and spacing used during 
acquisition of the post-operative MR images (Fig. 1c). The 
3D models created in Inventor were imported into Com-
sol (Comsol Inc., MA) and discretized into a finite ele-
ment mesh. Material properties of biological tissue used 
for performing the simulation are described in Table  3. 
The simulation was performed for a single pulse applied 
between pairs of electrodes used for treatment delivery 
in patients, and the electric field resulting from each such 
application was used to arrive at the cumulative electric 
field distribution at the end of treatment. Isoelectric con-
tours were drawn at 100  V/cm intervals (500–1500  V/
cm) for comparison with follow up MR imaging. The iso-
electric contours were used to identify the electric field 
threshold (Fig.  1d) that best matched with the ablation 
defect seen on follow-up MR imaging (Fig. 1c).
Statistical analysis
Patient data was compiled from a review of all medical, 
imaging and pathological reports. Results of simulation 
studies were compared to outcomes determined by clini-
cal data (PSA, quality of life survey) as well as follow-up 
MR imaging. The size of the ablation as estimated by 
numerical simulation and the actual ablation defect seen 
on MR imaging was compared and statistically analyzed 
for significance. Our study attempts to demonstrate that 
simulation model estimated ablation defect will not be 
different (or non-inferior) to the ablation defect measured 
on MR imaging. This requires a total of four samples per 
group to determine non-inferiority at 95  % confidence 
interval. In our case, the control (MRI) and treatment 
(simulation) data is drawn from the same patient, and our 
study was conducted using six patients (25 % more than 
what is required to achieve statistical power). Statistical 
Table 1 Patient characteristics and ablations data
Clinical history IRE treatment information








1 68 Active surv 
(2009)
T1c 6 (3 + 3) 4 15 (11–19) 2330 (1650–2850) 90 4
2 70 New Diag. T1c
Apex
6 (3 + 3) 5 13.7 (11–19) 2103 (1650–2850) 90 7
3 64 New Diag. T1c
Apex right
6 (3 + 3) 3 13.3 (13–14) 2000 (1950–2100) 90 3
4 61 New Diag. T1cApex right 6 (3 + 3) 4 12.2 (10–14) 2075 (1700–2340) 90 4
5 70 Radioth 2008 T2a
PZ right
9 (4 + 5) 5 14 (11–16) 2301 (1760–2720) 90 7
6 66 New Diag. T1c
Apex
6 (3 + 3) 3 14 (13–15) 2520 (2340–2700) 90 3
Table 2 MR imaging protocol used during follow-up imag-
ing
MRI magnetic resonance imaging, DWI diffusion weighted imaging, FOV field of 
view, SE spin echo, EPI echo planar imaging, GE gradient echo
MRI protocol MRI Sequences
T1 weighted T2 weighted DWI Dynamic
SE SE EPI GE
Plane Axial Axial Axial Axial
Time to repeat 
(ms)
646 6450 4500 3.77
Time to echo 
(ms)
12 116 91 1.46
Angulation (°) 134 170 10
Thickness (mm) 3.5 3.5 3.5 3.5
FOV (mm) 160 150 180 190
Matrix 
(mm × mm)
246 × 256 246 × 256 102 × 128 128 × 160
Scan time (s) 150 390 340 260
Time resolution 
(s)
– – – 10
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analysis was conducted with Fisher exact test, χ2 for inde-
pendence test (Excel; Microsoft, Redmond, WA) and 
p  <  0.05 was considered significant. The ablation zones 
from the simulation and MR imaging were also evaluated 
using Pearson product moment correlation.
Results
Imaging outcomes
In the immediate post-treatment setting, non-contrast 
US images indicated presence of multiple diffuse regions 
with hyperechoic appearance within the ablation zone. 
Fig. 1 Overview of workflow used to perform patient specific simulation for IRE treatment performed on a 70-year-old man with Gleason 9 recur-
rence after radiation therapy (patient 6). a T1 weighted post contrast MRI showed a tumor (center marked with an asterisk, boundary with solid line) 
in the right peripheral zone. b Intra-operative axial US guided needle placement to the tumor (5 IRE needles, white arrows). The intra-operative US 
image annotated to demarcate the ablation probes (dashed arrows), the outline of the prostate, the rectum, and the neurovascular bundles (NVB) 
(solid lines). Clinical treatment planning data were compiled and the MR images from the corresponding axial plane were used to identify critical 
structures for segmentation. c Follow-up axial enhanced T1w with fat saturation MR imaging performed 15 days after ablation was used to demar-
cate the ablation defect (solid line) and showed size and shape of the ablative zone (area: 701 mm2). d Simulation predicted ablation zone (white 
with blue boundary) at the electric field strength contour (700 V/cm; area 624 mm2, arrowhead). Image plotted using gradient shading with regions 
of highest field strength (700 V/cm and stronger) appearing light and lower field strengths appearing dark. Simulation predicted that ablation 
encompassed completely the tumor
Table 3 Tissue electrical properties used in numerical simulation
Tissue type Electrical conductivity S/m References
Healthy prostate 0.41 Neal et al. (2014), Daniels and Rubinsky (2012), Halter et al. (2009)
Prostate tumor 0.3 Neal et al. (2014), Daniels and Rubinsky (2012), Halter et al. (2009)
Axon 1.44 Daniels and Rubinsky (2012)
Fat 0.012 Daniels and Rubinsky (2012)
Blood 0.7 Daniels and Rubinsky (2012)
Muscle 0.2 Daniels and Rubinsky (2012)
Colon 0.01 Daniels and Rubinsky (2012)
Page 5 of 9Srimathveeravalli et al. SpringerPlus  (2016) 5:219 
There was also the occasional appearance of a hyper-
echoic region at the margin of the planned treatment 
zone. However, this was not clearly present in the entire 
treatment region and was not observed in all patients.
It was possible to discriminate between treated and 
untreated regions of the gland on follow-up MR imag-
ing. The expected treatment zone appeared as a hetero-
geneous hypointense zone on T1 imaging, but it was not 
possible to clearly separate the treated region from sur-
rounding normal gland. On T2 imaging, the ablation 
zone appeared as a hyperintense region interspersed with 
low intensity locations that were consistent with abla-
tion probe tract (Fig. 2a). On contrast-enhanced dynamic 
T1 imaging performed with fat suppression, the treat-
ment region appeared non-enhancing with limited to no 
enhancement of tissue in the periphery (Fig. 2b). The T2 
and contrast-enhanced dynamic T1 images were used to 
identify and segment the expected ablation zone for com-
parison with simulation results.
It was possible to obtain good registration of the intra-
operative US and the follow-up MR imaging. The follow-
ing results were obtained from computing the ratio of 
prostate’s area as measured with the two modalities at the 
registered slice (mean 0.99, range 0.86–1.07). The meas-
ured area of the prostate from the two modalities were 
not significantly different (p = 0.49, see Table 4).
Simulation outcomes
Individualized models were created and simulations 
performed for every patient included in this study (for 
example; Fig.  1). Simulation findings suggest that the 
ablative electric field was not restricted to the prostate, 
and was seen penetrating peri-prostatic fat and muscle 
in all patients (Fig.  3). In all simulations, the maximum 
electric field strength in sensitive structures adjacent to 
the prostate, such as the neurovascular bundle (<300 V/
cm) or the rectum (<600 V/cm), were at levels at which 
minimal or no IRE induced damage was expected at 
these structures. An electric field gradient was developed 
within the prostate from application of voltage between 
electrodes, and the electric field was strongest in the 
immediate vicinity of the ablation probes. The electric 
field was estimated to completely cover the tumor in the 
two cases where tumors were identifiable on pre-opera-
tive MR images. Simulations estimated an irregular and 
non-convex ablation zone in all patients. None of the 
ablations performed between any pair of needle elec-
trodes was observed to have a regular convex ellipsoidal 
shape in the axial cross section. Metallic objects in the 
vicinity of the treatment zone were observed to influence 
the electric field distribution. This effect largely appeared 
with exposed ablation probe tips present in the treatment 
region, but not actively used for energy delivery (Fig. 4; 
energy delivery was performed between one pair of abla-
tion probes at a time).
Comparison of simulation and follow‑up imaging
The contour plot of electric field strength from the simu-
lation was registered and compared with follow-up MR 
images to identify the electric field strength threshold 
that matched with the size of the post-ablation defect 
on imaging. It was found that the electric field strength 
contour at 700 V/cm correlated closely with the follow-
up MR images (Simulation predicted ablation area: 
532.33  mm2 in mean for all patients vs Ablation area 
measured on imaging: 540.16  mm2 in mean, p  =  0.43) 
Fig. 2 Typical findings on follow-up MRI 3 weeks after IRE of the prostate. From one patient, a the treatment zone appears as heterogeneous hyper-
intense region (arrow) with regions of low signal intensity. b The lesion (arrow) is easily visualized on contrast enhanced T1w imaging
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for all patient cases reviewed. This threshold was used to 
demarcate the expected ablation zone within the pros-
tate and measurements (area and cross section) were 
performed using GIMP and presented in Table  4. Radi-
ologist interpretation from two separate observers (F.C. 
and H.T.) suggested that the shape and size of the abla-
tion predicted by the simulation compared well with all 
post-operative MR imaging in all cases. The two meas-
urements had a correlation coefficient of 0.945 when 
evaluated using Pearson product moment technique. The 
ratio of measurements taken from the two modalities 
also indicated good correspondence between the tech-
niques (mean 0.97; range 0.61–1.2).
Patients reported outcomes
Evaluation of the self reported forms suggested that none 
of the patients undergoing IRE therapy developed impo-
tence or urinary incontinence following treatment. A sig-
nificant decrease of PSA (p =  0.01) was observed in all 
patients during clinical follow-up. Clinical outcomes are 
summarized in Table 5.
Discussion
Irreversible electroporation for the focal ablation of 
prostate is a new treatment technique and has seen use 
at just select centers in the world (Valerio et  al. 2014). 
The ability to perform non-thermal treatment with IRE 
makes it a valuable clinical alternative to existing ther-
mal ablation techniques such as HIFU or cryotherapy. 
However, there exist considerable knowledge gaps on 
the typical imaging findings, and treatment outcomes 
following IRE of prostate, and this has restricted wider 
use of this technique. Currently, it is not possible to 
directly measure the electric field strength generated 
in the targeted tissue during IRE. Therefore unlike 
HIFU, where MR imaging can be employed to moni-
tor temperatures and subsequently estimate the effec-
tive treatment zone, there is no simple way to predict 
the expected ablation zone following IRE. Therefore 
treatment planning may be crucial for guiding the safe 
delivery of IRE in patients. Our results demonstrate the 
feasibility of using numerical simulations constructed 
with pre-operative MR images and intra-operative US 
to estimate the treatment zone, which was comparable 
to what was observed on follow-up MR imaging. In the 
future, such simulations could potentially be used to 
plan and guide IRE treatment in patients in a prospec-
tive fashion.
Table 4 Area of prostate (mm2) observed with MRI and US 
at the same level
Size of the prostate ablation observed with MRI and based on simulation (with a 
threshold level of sensitivity of 700 V/m2)
Axial cross sectional area of the prostate of the post-treatment MRI and US were 
compared to validate the accuracy of registration. The US and simulation image 
are at 1:1 scaling
Patient Axial cross‑sectional area 
of prostate (mm2)
Axial cross‑sectional area 
of ablation zone (mm2)
MRI US MRI Simulation
1 2055 1916 590 585
2 1966 1877 849 735
3 1420 1633 210 340
4 888 895 322 449
5 1309 1377 701 624
6 1741 1682 569 461








p Not significant: (0.49) Not significant: (0.43)
Fig. 3 Simulation findings suggest that the ablative electric field was not restricted to the prostate, and was seen penetrating peri-prostatic fat 
and muscle tissue. Neurovascular bundle and rectal tissues may be drawing the ablative electric field towards them and thereby affecting the 
size and shape of the ablation within the prostate. a The neurovascular bundle influenced the shape of the electric field in ablations performed in 
the periphery of the prostate (arrow) (patient 1). b The rectum was seen to be influencing the electric field of ablations performed centrally in the 
prostate (arrow)
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As a focal ablation technique, post-treatment imag-
ing findings are crucial to understand tissue ablation 
with IRE, and also to prognosticate treatment outcomes. 
MRI findings have been previously reported for the acute 
effects and short-term injury evolution following IRE in 
different animal models, including work by Zhang et al. 
(2014) in rats with hepatoma, and Wendler et al. (2013) in 
normal swine kidney. There is limited published informa-
tion on the typical imaging findings following IRE in the 
prostate and while not the primary focus of this work, we 
report our imaging findings. Consistent to prior reports 
from animal models studies, MR imaging following IRE 
presents as a heterogenous region with both hyper and 
hypointense regions on T1 and T2w imaging. The abla-
tion zone was best visualized using contrast enhanced 
T1w imaging, appearing as a region of non-enhancement 
when compared to untreated gland. Also, imaging find-
ings observed by us on US following IRE were similar 
to previously reported findings after IRE in solid organs 
(Schmidt et  al. 2012). However, further study is war-
ranted before these findings can be translated into clini-
cal meaningful results.
The ablation boundary estimated at the threshold field 
strength of 700 V/cm in simulations correlated well with 
the post-operative MR images from our patients. Prior 
reports from in  vivo studies performed on healthy dog 
prostate suggest irreversible damage to cells in regions 
that experienced electric field strength of 600  V/cm 
or higher (Onik et  al. 2007). A study performed by Qin 
et  al. (2013) using a LNCaP tumor model suggests that 
the critical field strength required for achieving irrevers-
ible contingent can range from 600 to 1300  V/cm, and 
will vary based on the number of pulses applied and the 
pulse duration. Our results are in agreement with these 
prior studies. However, a study performed by Neal et al. 
(2014) with simulation-pathology correlation of human 
prostates resected 3–4  weeks following IRE ablation 
reported a higher threshold for IRE induced cell death 
(1072  V/cm). While this study used volumetric mod-
eling of the ablation zone and a different simulation tech-
nique, the study results are restricted by the small dataset 
(two patients) used for their simulations. Since we did 
not have pathology following ablation from the patients 
enrolled in this study, 700 V/cm as the critical threshold 
Fig. 4 The effect of exposed but unused ablation probes on ablation outcomes. a Simulation representing actual clinical scenario where unused 
ablation probes are left exposed in the prostate while ablation is delivered through the other pair of ablations probes (white arrow indicates current 
drawn around un-insulated probe not used for ablation) (patient 4). b Simulation representing scenario if the unused probe had been insulated 
prior to delivering ablation between the other two probes (white arrow)
Table 5 Clinical outcomes following treatment
Patient Follow‑up MRI (days) Post‑op biopsy  
(outcome)
Most recent post‑op 
PSA (months)
PSA (pre)  
(ng/ml)
PSA (post)  
(ng/ml)
Potent Continent
1 35 +ve 7 3.96 3 Yes Yes
2 23 +ve 11 1.9 1.24 Yes Yes
3 29 +ve 6 5.59 4.44 Yes Yes
4 22 −ve 7 1.71 1.12 Yes Yes
5 15 −ve 8 5.63 1.1 Yes Yes
6 10 −ve 9 5.42 3.15 Yes Yes
Mean (SD) 22.3 (±9.07) 8 (±1.78) 4.03 (±1.83) 2.17 (±1.59)
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is drawn purely in correlation to MR imaging informa-
tion. A larger study may be required before the differ-
ences between imaging and pathology measurements 
can be clarified, and until such time our findings should 
only be taken in context of post-IRE MR imaging of the 
prostate.
Confirming findings from the large animal study 
reported by Ben-David et al. (2013), the in vivo distribu-
tion of the ablative electric field that induces IRE in the 
tissue was found susceptible to regional heterogeneities 
in electrical conductivity. During IRE treatment all abla-
tion probes to be used for the treatment are inserted 
together in a pre-determined configuration along the 
long axis of urethra, and subsequently treatment is deliv-
ered between select pairs of ablations probes. Simulation 
electric field maps suggest that the electric field may get 
drawn towards the exposed tips of the unused probes 
(Fig. 4).
Our retrospective patient-specific simulations sug-
gested lack of injury to the neurovascular bundle and 
rectum in our patient cohort, and these findings were 
reflected in the patient reported outcomes. Our simula-
tion results suggested that IRE mediated tissue destruc-
tion was largely restricted to the prostate. Despite being 
in proximity to the ablation zone, simulation indicated 
the sparing of the rectum, neurovascular bundle and the 
urethra. In agreement with simulation findings, no impo-
tency or incontinence has been reported during a mean 
follow up time of 8 months following treatment.
Our study has a few limitations, primarily the explora-
tory nature of the work and the small number of patients 
enrolled in this study. These factors may limit the gener-
alization of our findings. The simulation was performed 
using data segmented from intra-operative US images, 
which has less information than the pre-operative MR 
images. Complex and heterogeneous structures such as 
the neurovascular bundle were represented in the model 
as simpler lumped structures with homogenous electri-
cal properties which reduce precision of the simulation 
model. Our simulation was not truly volumetric and 
was restricted to a single thick slice of tissue and there-
fore may not estimate the behavior of the entire abla-
tion volume. Our results are pertinent for comparison of 
simulation findings with post-treatment imaging, and the 
absence of pathology data limits drawing definitive con-
clusions on the status of the treated tissue. Post-ablation 
tissue is constantly evolving, undergoing edema and tis-
sue expansion in the early phase followed by fibrosis and 
tissue shrinkage at later periods. These dynamic changes 
may explain some of the inter-patient differences in sim-
ulation versus MRI measurements we observed. Finally, 
gadolinium-enhanced MRI by itself is not a validated 
technique for measuring the effectiveness of IRE in the 
prostate; therefore, we are unable to arrive at any conclu-
sion on the value of simulations for estimating true treat-
ment outcomes.
In summary, our results suggest that simulation of 
IRE ablation matches treatment zones seen on MRI, and 
therefore may help in treatment planning of ultrasound-
guided IRE in the prostate. While we provide evidence 
that simulations can be used to estimate the size and 
shape of the expected IRE ablation in patient prostate 
with good correlation to MR imaging, further compari-
son with pathology are required before using simulations 
to predict treatment efficacy.
Conclusions
It is feasible to use mathematical modeling and simula-
tion to estimate the effects of irreversible electropora-
tion in patient prostate. Simulations estimated size and 
shape of treatment zone correlates with ablation defect 
seen on MR imaging following IRE of the prostate. Iso-
electric contour at 700 V/cm on simulation can be used 
to determine expected treatment effect as seen on post-
treatment MR imaging.
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